Targeting HGF/c-MET Axis in Pancreatic Cancer
نویسندگان
چکیده
منابع مشابه
Targeting MET in cancer therapy
MET encodes a receptor tyrosine kinase c-MET for hepatocyte growth factor (HGF). The specific combination of c-MET and HGF activates downstream signaling pathways to trigger cell migration, proliferation, and angiogenesis. MET exon 14 alterations and MET gene amplification play a critical role in the origin of cancer. Several monoclonal antibodies and small-molecule inhibitors of c-MET have bee...
متن کاملTargeting MET in Lung Cancer: Will Expectations Finally Be MET?
The hepatocyte growth factor receptor (MET) is a potential therapeutic target in a number of cancers, including NSCLC. In NSCLC, MET pathway activation is thought to occur through a diverse set of mechanisms that influence properties affecting cancer cell survival, growth, and invasiveness. Preclinical and clinical evidence suggests a role for MET activation as both a primary oncogenic driver i...
متن کاملTargeting MET in Cancer: Obstacles and Potentials
MET is a tyrosine kinase receptor involved in cell proliferation, survival, and migration. MET pathway is activated in cancer by gene amplification and overexpression, ligand overexpression and autocrine/paracrine activation, and activating MET mutations. MET dysregulation is also found to be responsible for resistance to treatment and targeted therapy including EGFR TKIs for NSCLC. Preclinical...
متن کاملTargeting the HGF/c-Met axis: state of play.
In a recent issue ofMolecular Cancer Therapeutics, Burgess and colleagues (1) give a detailed biochemical and functional characterization of AMG 102, a fully humanized monoclonal antibody to hepatocyte growth factor (HGF). HGF, or scatter factor, is the only known high-affinity ligand for the c-Met receptor tyrosine kinase (2). Upon ligand binding, c-Met undergoes dimerization, autophosphorylat...
متن کاملCrizotinib Exhibits Antitumor Activity by Targeting ALK Signaling not c-MET in Pancreatic Cancer
Crizotinib, a c-MET/ALK inhibitor, has exhibited antitumor efficacy in different types of cancers. However, studies regarding Crizotinib in pancreatic cancer have been limited. Thus, we investigated the effect of Crizotinib on pancreatic cancer and its mechanism of action. Crizotinib strongly suppressed the growth and proliferation of pancreatic cancer cells in a dose-dependent manner. Also, it...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Molecular Sciences
سال: 2020
ISSN: 1422-0067
DOI: 10.3390/ijms21239170